Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017:2017:8137078.
doi: 10.1155/2017/8137078. Epub 2017 May 10.

Cisplatin-Induced Renal Salt Wasting Requiring over 12 Liters of 3% Saline Replacement

Affiliations
Case Reports

Cisplatin-Induced Renal Salt Wasting Requiring over 12 Liters of 3% Saline Replacement

Phuong-Chi Pham et al. Case Rep Nephrol. 2017.

Abstract

Cisplatin is known to induce Fanconi syndrome and renal salt wasting (RSW). RSW typically only requires transient normal saline (NS) support. We report a severe RSW case that required 12 liters of 3% saline. A 57-year-old woman with limited stage small cell cancer was admitted for cisplatin (80 mg/m2) and etoposide (100 mg/m2) therapy. Patient's serum sodium (SNa) decreased from 138 to 133 and 125 mEq/L within 24 and 48 hours of cisplatin therapy, respectively. A diagnosis of syndrome of inappropriate antidiuretic hormone secretion (SIADH) was initially made. Despite free water restriction, patient's SNa continued to decrease in association with acute onset of headaches, nausea, and dizziness. Three percent saline (3%S) infusion with rates up to 1400 mL/day was required to correct and maintain SNa at 135 mEq/L. Studies to evaluate Fanconi syndrome revealed hypophosphatemia and glucosuria in the absence of serum hyperglycemia. The natriuresis slowed down by 2.5 weeks, but 3%S support was continued for a total volume of 12 liters over 3.5 weeks. Attempts of questionable benefits to slow down glomerular filtration included the administration of ibuprofen and benazepril. To our knowledge, this is the most severe case of RSW ever reported with cisplatin.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Dasari S., Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology. 2014;740:364–378. doi: 10.1016/j.ejphar.2014.07.025. - DOI - PMC - PubMed
    1. Oh G.-S., Kim H.-J., Shen A., et al. Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolyte and Blood Pressure. 2014;12(2):55–65. doi: 10.5049/EBP.2014.12.2.55. - DOI - PMC - PubMed
    1. Florea A.-M., Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011;3(1):1351–1371. doi: 10.3390/cancers3011351. - DOI - PMC - PubMed
    1. Hamdi T., Latta S., Jallad B., Kheir F., Alhosaini M. N., Patel A. Cisplatin-induced renal salt wasting syndrome. Southern Medical Journal. 2010;103(8):793–799. doi: 10.1097/SMJ.0b013e3181e63682. - DOI - PubMed
    1. Lammers P. J., White L., Ettinger L. J. Cis‐platinum‐induced renal sodium wasting. Medical and Pediatric Oncology. 1984;12(5):343–346. doi: 10.1002/mpo.2950120509. - DOI - PubMed

Publication types

LinkOut - more resources